On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) in combination with Tecentriq (atezolizumab) or Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as maintenance therapy for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease [...]